ReWalk Robotics’ (LFWD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of ReWalk Robotics (NASDAQ:LFWD) in a report issued on Wednesday morning,Benzinga reports. They currently have a $13.00 price objective on the stock.

ReWalk Robotics Stock Up 0.5 %

LFWD stock traded up $0.01 during trading on Wednesday, hitting $2.01. 631 shares of the company’s stock traded hands, compared to its average volume of 42,833. The business has a fifty day simple moving average of $2.79 and a two-hundred day simple moving average of $3.69. The firm has a market capitalization of $17.64 million, a P/E ratio of -0.81 and a beta of 2.07. ReWalk Robotics has a 1 year low of $1.97 and a 1 year high of $9.10.

ReWalk Robotics (NASDAQ:LFWD) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $6.71 million for the quarter, compared to analyst estimates of $6.71 million. ReWalk Robotics had a negative return on equity of 41.10% and a negative net margin of 77.21%. During the same quarter in the previous year, the firm earned ($0.35) earnings per share. On average, equities research analysts predict that ReWalk Robotics will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On ReWalk Robotics

A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP purchased a new stake in ReWalk Robotics Ltd. (NASDAQ:LFWD) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned 0.16% of ReWalk Robotics as of its most recent filing with the SEC. 26.76% of the stock is owned by institutional investors.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.